ANP.AX Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 saus. 2024 @ 06:56):

Stats
Dzisiejszy wolumen	869 280
Średni wolumen	548 968
Kapitalizacja rynkowa	52.29M
EPS	$0 ( 2024-02-19 )
Następna data zysków	( $0 ) 2024-07-26
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.90
ATR14	$0.00300 (5.36%)

Wolumen Korelacja

Długi: -0.22 (neutral)

Krótki: -0.74 (moderate negative)

Signal:(44.832) Neutral

Antisense Therapeutics Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Antisense Therapeutics Korelacja - Waluta/Towar

-0.68
( moderate negative )

-0.56
( weak negative )

0.00
( neutral )

0.47
( neutral )

Antisense Therapeutics Finanse

Annual	2022
Przychody:	$1.58M
Zysk brutto:	$1.55M (97.91 %)
EPS:	$-0.0179

FY	2022
Przychody:	$1.58M
Zysk brutto:	$1.55M (97.91 %)
EPS:	$-0.0179

FY	2022
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$-0.00920

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.0209

Financial Reports:

No articles found.

Antisense Therapeutics

Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase II clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited was incorporated in 2000 and is based in Toorak, Australia.